Industry Research Reports

Home > Reports > Pharma & Healthcare > Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published Date: 2024-01-11

Pages: 122 Pages

Report ld: 3032136

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

MARKET SEGMENTATION

By Company

Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

150 mg/mL
75 mg/0.5 mL

Segment by Application

Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Omalizumab Biosimilars, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Omalizumab Biosimilars by region & country, by Type, and by Application.

The Omalizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Biosimilars.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Omalizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Omalizumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Omalizumab Biosimilars in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Omalizumab Biosimilars Product Introduction

1.2 Global Omalizumab Biosimilars Market Size Forecast

1.2.1 Global Omalizumab Biosimilars Sales Value (2019-2030)

1.2.2 Global Omalizumab Biosimilars Sales Volume (2019-2030)

1.2.3 Global Omalizumab Biosimilars Sales Price (2019-2030)

1.3 Omalizumab Biosimilars Market Trends & Drivers

1.3.1 Omalizumab Biosimilars Industry Trends

1.3.2 Omalizumab Biosimilars Market Drivers & Opportunity

1.3.3 Omalizumab Biosimilars Market Challenges

1.3.4 Omalizumab Biosimilars Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Omalizumab Biosimilars Players Revenue Ranking (2023)

2.2 Global Omalizumab Biosimilars Revenue by Company (2019-2024)

2.3 Global Omalizumab Biosimilars Players Sales Volume Ranking (2023)

2.4 Global Omalizumab Biosimilars Sales Volume by Company Players (2019-2024)

2.5 Global Omalizumab Biosimilars Average Price by Company (2019-2024)

2.6 Key Manufacturers Omalizumab Biosimilars Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Omalizumab Biosimilars Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Omalizumab Biosimilars

2.9 Omalizumab Biosimilars Market Competitive Analysis

2.9.1 Omalizumab Biosimilars Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Omalizumab Biosimilars Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 150 mg/mL

3.1.2 75 mg/0.5 mL

3.2 Global Omalizumab Biosimilars Sales Value by Type

3.2.1 Global Omalizumab Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Omalizumab Biosimilars Sales Value, by Type (2019-2030)

3.2.3 Global Omalizumab Biosimilars Sales Value, by Type (%) (2019-2030)

3.3 Global Omalizumab Biosimilars Sales Volume by Type

3.3.1 Global Omalizumab Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Omalizumab Biosimilars Sales Volume, by Type (2019-2030)

3.3.3 Global Omalizumab Biosimilars Sales Volume, by Type (%) (2019-2030)

3.4 Global Omalizumab Biosimilars Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Persistent Asthma

4.1.2 Nasal Polyps

4.1.3 Chronic Idiopathic Urticaria

4.2 Global Omalizumab Biosimilars Sales Value by Application

4.2.1 Global Omalizumab Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Omalizumab Biosimilars Sales Value, by Application (2019-2030)

4.2.3 Global Omalizumab Biosimilars Sales Value, by Application (%) (2019-2030)

4.3 Global Omalizumab Biosimilars Sales Volume by Application

4.3.1 Global Omalizumab Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Omalizumab Biosimilars Sales Volume, by Application (2019-2030)

4.3.3 Global Omalizumab Biosimilars Sales Volume, by Application (%) (2019-2030)

4.4 Global Omalizumab Biosimilars Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Omalizumab Biosimilars Sales Value by Region

5.1.1 Global Omalizumab Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Omalizumab Biosimilars Sales Value by Region (2019-2024)

5.1.3 Global Omalizumab Biosimilars Sales Value by Region (2025-2030)

5.1.4 Global Omalizumab Biosimilars Sales Value by Region (%), (2019-2030)

5.2 Global Omalizumab Biosimilars Sales Volume by Region

5.2.1 Global Omalizumab Biosimilars Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Omalizumab Biosimilars Sales Volume by Region (2019-2024)

5.2.3 Global Omalizumab Biosimilars Sales Volume by Region (2025-2030)

5.2.4 Global Omalizumab Biosimilars Sales Volume by Region (%), (2019-2030)

5.3 Global Omalizumab Biosimilars Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Omalizumab Biosimilars Sales Value, 2019-2030

5.4.2 North America Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Omalizumab Biosimilars Sales Value, 2019-2030

5.5.2 Europe Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Omalizumab Biosimilars Sales Value, 2019-2030

5.6.2 Asia Pacific Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Omalizumab Biosimilars Sales Value, 2019-2030

5.7.2 South America Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Omalizumab Biosimilars Sales Value, 2019-2030

5.8.2 Middle East & Africa Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Omalizumab Biosimilars Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Omalizumab Biosimilars Sales Value

6.2.1 Key Countries/Regions Omalizumab Biosimilars Sales Value, 2019-2030

6.2.2 Key Countries/Regions Omalizumab Biosimilars Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Omalizumab Biosimilars Sales Value, 2019-2030

6.3.2 United States Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Omalizumab Biosimilars Sales Value, 2019-2030

6.4.2 Europe Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Omalizumab Biosimilars Sales Value, 2019-2030

6.5.2 China Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.5.3 China Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Omalizumab Biosimilars Sales Value, 2019-2030

6.6.2 Japan Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Omalizumab Biosimilars Sales Value, 2019-2030

6.7.2 South Korea Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Omalizumab Biosimilars Sales Value, 2019-2030

6.8.2 Southeast Asia Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Omalizumab Biosimilars Sales Value, 2019-2030

6.9.2 India Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

6.9.3 India Omalizumab Biosimilars Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Roche

7.1.1 Roche Company Information

7.1.2 Roche Introduction and Business Overview

7.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Roche Omalizumab Biosimilars Product Offerings

7.1.5 Roche Recent Development

7.2 Novartis

7.2.1 Novartis Company Information

7.2.2 Novartis Introduction and Business Overview

7.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Novartis Omalizumab Biosimilars Product Offerings

7.2.5 Novartis Recent Development

7.3 Glenmark Pharmaceuticals

7.3.1 Glenmark Pharmaceuticals Company Information

7.3.2 Glenmark Pharmaceuticals Introduction and Business Overview

7.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Offerings

7.3.5 Glenmark Pharmaceuticals Recent Development

7.4 Selexis

7.4.1 Selexis Company Information

7.4.2 Selexis Introduction and Business Overview

7.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Selexis Omalizumab Biosimilars Product Offerings

7.4.5 Selexis Recent Development

7.5 Generium

7.5.1 Generium Company Information

7.5.2 Generium Introduction and Business Overview

7.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Generium Omalizumab Biosimilars Product Offerings

7.5.5 Generium Recent Development

7.6 CuraTeQ

7.6.1 CuraTeQ Company Information

7.6.2 CuraTeQ Introduction and Business Overview

7.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.6.4 CuraTeQ Omalizumab Biosimilars Product Offerings

7.6.5 CuraTeQ Recent Development

7.7 Celltrion Healthcare

7.7.1 Celltrion Healthcare Company Information

7.7.2 Celltrion Healthcare Introduction and Business Overview

7.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Offerings

7.7.5 Celltrion Healthcare Recent Development

7.8 Alvotech

7.8.1 Alvotech Company Information

7.8.2 Alvotech Introduction and Business Overview

7.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Alvotech Omalizumab Biosimilars Product Offerings

7.8.5 Alvotech Recent Development

7.9 BiosanaPharma

7.9.1 BiosanaPharma Company Information

7.9.2 BiosanaPharma Introduction and Business Overview

7.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.9.4 BiosanaPharma Omalizumab Biosimilars Product Offerings

7.9.5 BiosanaPharma Recent Development

7.10 Mabpharm

7.10.1 Mabpharm Company Information

7.10.2 Mabpharm Introduction and Business Overview

7.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Mabpharm Omalizumab Biosimilars Product Offerings

7.10.5 Mabpharm Recent Development

7.11 CSPC Pharmaceutical Group

7.11.1 CSPC Pharmaceutical Group Company Information

7.11.2 CSPC Pharmaceutical Group Introduction and Business Overview

7.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Offerings

7.11.5 CSPC Pharmaceutical Group Recent Development

7.12 Biomabs

7.12.1 Biomabs Company Information

7.12.2 Biomabs Introduction and Business Overview

7.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Biomabs Omalizumab Biosimilars Product Offerings

7.12.5 Biomabs Recent Development

7.13 HisunPharm

7.13.1 HisunPharm Company Information

7.13.2 HisunPharm Introduction and Business Overview

7.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)

7.13.4 HisunPharm Omalizumab Biosimilars Product Offerings

7.13.5 HisunPharm Recent Development

8 Industry Chain Analysis

8.1 Omalizumab Biosimilars Industrial Chain

8.2 Omalizumab Biosimilars Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Omalizumab Biosimilars Sales Model

8.5.2 Sales Channel

8.5.3 Omalizumab Biosimilars Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Omalizumab Biosimilars Market Trends

Table 2. Omalizumab Biosimilars Market Drivers & Opportunity

Table 3. Omalizumab Biosimilars Market Challenges

Table 4. Omalizumab Biosimilars Market Restraints

Table 5. Global Omalizumab Biosimilars Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Omalizumab Biosimilars Revenue Market Share by Company (2019-2024)

Table 7. Global Omalizumab Biosimilars Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Omalizumab Biosimilars Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Omalizumab Biosimilars Price by Company (2019-2024) & (USD/Unit)

Table 10. Key Manufacturers Omalizumab Biosimilars Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Omalizumab Biosimilars Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Omalizumab Biosimilars

Table 13. Global Omalizumab Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Omalizumab Biosimilars Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Omalizumab Biosimilars Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Omalizumab Biosimilars Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Omalizumab Biosimilars Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Omalizumab Biosimilars Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Omalizumab Biosimilars Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Omalizumab Biosimilars Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Omalizumab Biosimilars Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Omalizumab Biosimilars Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Omalizumab Biosimilars Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Omalizumab Biosimilars Price by Type (2019-2024) & (USD/Unit)

Table 27. Global Omalizumab Biosimilars Price by Type (2025-2030) & (USD/Unit)

Table 28. Global Omalizumab Biosimilars Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Omalizumab Biosimilars Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Omalizumab Biosimilars Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Omalizumab Biosimilars Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Omalizumab Biosimilars Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Omalizumab Biosimilars Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Omalizumab Biosimilars Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Omalizumab Biosimilars Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Omalizumab Biosimilars Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Omalizumab Biosimilars Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Omalizumab Biosimilars Price by Application (2019-2024) & (USD/Unit)

Table 39. Global Omalizumab Biosimilars Price by Application (2025-2030) & (USD/Unit)

Table 40. Global Omalizumab Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Omalizumab Biosimilars Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Omalizumab Biosimilars Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Omalizumab Biosimilars Sales Value by Region (2019-2024) & (%)

Table 44. Global Omalizumab Biosimilars Sales Value by Region (2025-2030) & (%)

Table 45. Global Omalizumab Biosimilars Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Omalizumab Biosimilars Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Omalizumab Biosimilars Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Omalizumab Biosimilars Sales Volume by Region (2019-2024) & (%)

Table 49. Global Omalizumab Biosimilars Sales Volume by Region (2025-2030) & (%)

Table 50. Global Omalizumab Biosimilars Average Price by Region (2019-2024) & (USD/Unit)

Table 51. Global Omalizumab Biosimilars Average Price by Region (2025-2030) & (USD/Unit)

Table 52. Key Countries/Regions Omalizumab Biosimilars Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Omalizumab Biosimilars Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Omalizumab Biosimilars Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Omalizumab Biosimilars Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Omalizumab Biosimilars Sales Volume, (2025-2030) & (K Units)

Table 57. Roche Company Information

Table 58. Roche Introduction and Business Overview

Table 59. Roche Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Roche Omalizumab Biosimilars Product Offerings

Table 61. Roche Recent Development

Table 62. Novartis Company Information

Table 63. Novartis Introduction and Business Overview

Table 64. Novartis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 65. Novartis Omalizumab Biosimilars Product Offerings

Table 66. Novartis Recent Development

Table 67. Glenmark Pharmaceuticals Company Information

Table 68. Glenmark Pharmaceuticals Introduction and Business Overview

Table 69. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 70. Glenmark Pharmaceuticals Omalizumab Biosimilars Product Offerings

Table 71. Glenmark Pharmaceuticals Recent Development

Table 72. Selexis Company Information

Table 73. Selexis Introduction and Business Overview

Table 74. Selexis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 75. Selexis Omalizumab Biosimilars Product Offerings

Table 76. Selexis Recent Development

Table 77. Generium Company Information

Table 78. Generium Introduction and Business Overview

Table 79. Generium Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 80. Generium Omalizumab Biosimilars Product Offerings

Table 81. Generium Recent Development

Table 82. CuraTeQ Company Information

Table 83. CuraTeQ Introduction and Business Overview

Table 84. CuraTeQ Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 85. CuraTeQ Omalizumab Biosimilars Product Offerings

Table 86. CuraTeQ Recent Development

Table 87. Celltrion Healthcare Company Information

Table 88. Celltrion Healthcare Introduction and Business Overview

Table 89. Celltrion Healthcare Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 90. Celltrion Healthcare Omalizumab Biosimilars Product Offerings

Table 91. Celltrion Healthcare Recent Development

Table 92. Alvotech Company Information

Table 93. Alvotech Introduction and Business Overview

Table 94. Alvotech Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 95. Alvotech Omalizumab Biosimilars Product Offerings

Table 96. Alvotech Recent Development

Table 97. BiosanaPharma Company Information

Table 98. BiosanaPharma Introduction and Business Overview

Table 99. BiosanaPharma Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 100. BiosanaPharma Omalizumab Biosimilars Product Offerings

Table 101. BiosanaPharma Recent Development

Table 102. Mabpharm Company Information

Table 103. Mabpharm Introduction and Business Overview

Table 104. Mabpharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 105. Mabpharm Omalizumab Biosimilars Product Offerings

Table 106. Mabpharm Recent Development

Table 107. CSPC Pharmaceutical Group Company Information

Table 108. CSPC Pharmaceutical Group Introduction and Business Overview

Table 109. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 110. CSPC Pharmaceutical Group Omalizumab Biosimilars Product Offerings

Table 111. CSPC Pharmaceutical Group Recent Development

Table 112. Biomabs Company Information

Table 113. Biomabs Introduction and Business Overview

Table 114. Biomabs Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 115. Biomabs Omalizumab Biosimilars Product Offerings

Table 116. Biomabs Recent Development

Table 117. HisunPharm Company Information

Table 118. HisunPharm Introduction and Business Overview

Table 119. HisunPharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 120. HisunPharm Omalizumab Biosimilars Product Offerings

Table 121. HisunPharm Recent Development

Table 122. Key Raw Materials Lists

Table 123. Raw Materials Key Suppliers Lists

Table 124. Omalizumab Biosimilars Downstream Customers

Table 125. Omalizumab Biosimilars Distributors List

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Omalizumab Biosimilars Product Picture

Figure 2. Global Omalizumab Biosimilars Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Omalizumab Biosimilars Sales Volume (2019-2030) & (K Units)

Figure 5. Global Omalizumab Biosimilars Sales Price (2019-2030) & (USD/Unit)

Figure 6. Omalizumab Biosimilars Report Years Considered

Figure 7. Global Omalizumab Biosimilars Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Omalizumab Biosimilars Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Omalizumab Biosimilars Revenue in 2023

Figure 10. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. 150 mg/mL Picture

Figure 12. 75 mg/0.5 mL Picture

Figure 13. Global Omalizumab Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Omalizumab Biosimilars Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Omalizumab Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Omalizumab Biosimilars Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Omalizumab Biosimilars Price by Type (2019-2030) & (USD/Unit)

Figure 18. Product Picture of Persistent Asthma

Figure 19. Product Picture of Nasal Polyps

Figure 20. Product Picture of Chronic Idiopathic Urticaria

Figure 21. Global Omalizumab Biosimilars Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global Omalizumab Biosimilars Sales Value Market Share by Application, 2023 & 2030

Figure 23. Global Omalizumab Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 24. Global Omalizumab Biosimilars Sales Volume Market Share by Application, 2023 & 2030

Figure 25. Global Omalizumab Biosimilars Price by Application (2019-2030) & (USD/Unit)

Figure 26. North America Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 27. North America Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 28. Europe Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 29. Europe Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 30. Asia Pacific Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 32. South America Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 33. South America Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa Omalizumab Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 35. Middle East & Africa Omalizumab Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 36. Key Countries/Regions Omalizumab Biosimilars Sales Value (%), (2019-2030)

Figure 37. Key Countries/Regions Omalizumab Biosimilars Sales Volume (%), (2019-2030)

Figure 38. United States Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 39. United States Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 40. United States Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 41. Europe Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 42. Europe Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 43. Europe Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 44. China Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 45. China Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 46. China Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 47. Japan Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 48. Japan Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 49. Japan Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 50. South Korea Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 51. South Korea Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 52. South Korea Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 53. Southeast Asia Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 54. Southeast Asia Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 55. Southeast Asia Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 56. India Omalizumab Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 57. India Omalizumab Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 58. India Omalizumab Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 59. Omalizumab Biosimilars Industrial Chain

Figure 60. Omalizumab Biosimilars Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Omalizumab Biosimilars market? zhanKai

The top companies in the global Omalizumab Biosimilars market are Roche、Novartis、Glenmark Pharmaceuticals.

Related Reports

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 139
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-04-16
Pages: 164
USD 4900.00
(Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published Date: 2026-04-16
Pages: 142
USD 4250.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 120
USD 2900.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 90
USD 2900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 139
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-04-16
Pages: 164
USD 4900.00 (Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published: 2026-04-16
Pages: 142
USD 4250.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 120
USD 2900.00 (Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 90
USD 2900.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)